Fang Kong

Fang Kong

Auto-generated profile, based on publicly available information

Fang Kong

Beijing Frontier Research Center for Biological Structure, Beijing Advanced Innovation Center for Structural Biology, Tsinghua University, Beijing, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 July 2023 in Nature Structural & Molecular Biology
Verified
Journal Article
Closed access
PDF file
AZAngqi Zhu
Angqi Zhu
JHJunhao Huang
Junhao Huang
FKFang Kong
Fang Kong
JTJiaxin Tan
Jiaxin Tan
JLJianlin Lei
Jianlin Lei
CYChuangye Yan
Chuangye Yan

20 June 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
YTYosuke Toyoda
Yosuke Toyoda
AZAngqi Zhu
Angqi Zhu
FKFang Kong
Fang Kong
SSSisi Shan
Sisi Shan
JZJiawei Zhao
Jiawei Zhao
XLXiangyu Liu
Xiangyu Liu
The α1A-adrenergic receptor (α1AAR) belongs to the family of G protein-coupled receptors that respond to adrenaline and noradrenaline. α1AAR is involved in smooth muscle contraction and cognitive function. Here, we present three cryo-electron microscopy structures of human α1AAR bound to the endogenous agonist noradrenaline, its selective agonist oxymetazoline, and the antagonist tamsulosin, with resolutions range from 2.9 Å to 3.5 Å. Our active and inactive α1AAR structures reveal the activation mechanism and distinct ligand binding modes for noradrenaline compared with other adrenergic receptor subtypes. In addition, we identified a nanobody that preferentially binds to the extracellular vestibule of α1AAR when bound to the selective agonist oxymetazoline. These results should facilitate the design of more selective therapeutic drugs targeting both orthosteric and allosteric sites in this receptor family.

12 June 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
ZSZilin Shen
Zilin Shen
LXLi Xu
Li Xu
TWTong Wu
Tong Wu
HWHuan Wang
Huan Wang
QWQifan Wang
Qifan Wang
XPXiaojing Pan
Xiaojing Pan
Urate, the physiological form of uric acid and a potent antioxidant in serum, plays a pivotal role in scavenging reactive oxygen species. Yet excessive accumulation of urate, known as hyperuricemia, is the primary risk factor for the development of gout. The high-capacity urate transporter GLUT9 represents a promising target for gout treatment. Here, we present cryo-electron microscopy structures of human GLUT9 in complex with urate or its inhibitor apigenin at overall resolutions of 3.5 Å and 3.3 Å, respectively. In both structures, GLUT9 exhibits an inward open conformation, wherein the substrate binding pocket faces the intracellular side. These structures unveil the molecular basis for GLUT9’s substrate preference of urate over glucose, and show that apigenin acts as a competitive inhibitor by occupying the substrate binding site. Our findings provide critical information for the development of specific inhibitors targeting GLUT9 as potential therapeutics for gout and hyperuricemia.

24 July 2024 in Nature
Verified
Journal Article
Closed access
PDF file
JTJiaxin Tan
Jiaxin Tan
YXYuan Xiao
Yuan Xiao
FKFang Kong
Fang Kong
XZxiaochun zhang
xiaochun zhang
HXHanwen Xu
Hanwen Xu
CYChuangye Yan
Chuangye Yan

26 June 2025 in Science
Verified
Journal Article
Closed access
YZYing Zhang
Ying Zhang
LTLu Tian
Lu Tian
GHGaoxingyu Huang
Gaoxingyu Huang
XGXiaofei Ge
Xiaofei Ge
FKFang Kong
Fang Kong
YSYigong Shi
Yigong Shi
During apoptosis, cytosolic BAX monomers are translocated to the mitochondria to permeabilize the outer membrane. Here, we identified a dimer of BAX dimers as the basic repeating unit of its various oligomeric forms: arcs, lines, and rings. Cryo–electron microscopy structure of the BAX repeating unit at 3.2-angstrom resolution revealed the interactions within and between dimers. End-to-end stacking of the repeating units through the protruding α9 pairs yielded lines, arcs, polygons, and rings. We structurally characterized the tetragon, pentagon, hexagon, and heptagon, which comprise 16, 20, 24, and 28 BAX protomers, respectively. Missense mutations at the BAX inter-protomer interface damage pore formation and cripple its proapoptotic function. The assembly principle of the various BAX oligomers reported here provides the structural basis of membrane permeabilization by BAX.

15 March 2024 in Cell Discovery
Verified
Journal Article
Open access
PDF file
SZShuhao Zhang
Shuhao Zhang
AZAngqi Zhu
Angqi Zhu
FKFang Kong
Fang Kong
JCJianan Chen
Jianan Chen
BLBaoliang Lan
Baoliang Lan
XLXiangyu Liu
Xiangyu Liu
The human organic cation transporter 1 (hOCT1), also known as SLC22A1, is integral to hepatic uptake of structurally diversified endogenous and exogenous organic cations, influencing both metabolism and drug pharmacokinetics. hOCT1 has been implicated in the therapeutic dynamics of many drugs, making interactions with hOCT1 a key consideration in novel drug development and drug–drug interactions. Notably, metformin, the frontline medication for type 2 diabetes, is a prominent hOCT1 substrate. Conversely, hOCT1 can be inhibited by agents such as spironolactone, a steroid analog inhibitor of the aldosterone receptor, necessitating a deep understanding of hOCT1–drug interactions in the development of new pharmacological treatments. Despite extensive study, specifics of hOCT1 transport and inhibition mechanisms remain elusive at the molecular level. Here, we present cryo-electron microscopy structures of the hOCT1-metformin complex in three distinct conformational states — outward open, outward occluded, and inward occluded as well as substrate-free hOCT1 in both partially and fully open states. We also present hOCT1 in complex with spironolactone in both outward and inward facing conformations. These structures provide atomic-level insights into the dynamic metformin transfer process via hOCT1 and the mechanism by which spironolactone inhibits it. Additionally, we identify a ‘YER’ motif critical for the conformational flexibility of hOCT1 and likely other SLC22 family transporters. Our findings significantly advance the understanding of hOCT1 molecular function and offer a foundational framework for the design of new therapeutic agents targeting this transporter.